Why AstraZeneca and J&J’s Vaccines, In Use Elsewhere, Are Still on Hold in America
Covid has pressed the Food and Drug Administration into its fastest vaccine reviews ever — which are still painfully slow, critics say.
The independent source for health policy research, polling, and news.
281 - 300 of 471 Results
Covid has pressed the Food and Drug Administration into its fastest vaccine reviews ever — which are still painfully slow, critics say.
As experts race to get an approved test for covid variants, officials are severely restricted from sharing information about the cases. That makes it harder to protect others.
Even while the Senate is busy with Donald Trump’s impeachment trial, the House has gotten down to work on a covid relief bill using the budget reconciliation process. Meanwhile, the watchword for covid this week among the public is confusion — over masks, vaccines and just about everything else science-related. Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also this week, the panelists recommend their favorite “health policy valentines” along with their favorite health policy stories they think you should read, too.
With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
The federal government expects vaccinations to be available to everyone who wants them by summer — though glitches are inevitable. If enough of us get vaccinated, we could wave goodbye to the pandemic in 2021.
After missteps in Washington, each state and county is left to juggle where to send vaccines first and how to get them to each nursing home, hospital local health department and even school.
Even as the federal Food and Drug Administration engaged in intense deliberations ahead of Friday's authorization of the nation’s first COVID vaccine, and days before the initial doses were to be released, hospitals have been grappling with how to distribute the first scarce shots. Their plans vary broadly.
With two vaccines against coronavirus disease poised for release within weeks, experts say they expect attitudes to shift dramatically from hesitancy to “Beanie Baby”-level urgency.
Dentists and optometrists across the country are trying to join in the fight to get everyone vaccinated against COVID-19, the flu and other diseases.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
It typically takes months to install new leadership, but with COVID deaths set to surge through the winter, many Democrats say Biden doesn’t have that sort of time.
California and at least five other states have said they may independently vet any vaccines. Experts warn that could needlessly confuse the public.
Regulators and scientists have been leery of introducing the tests, preferring to rely on tried-and-true methods, but evidence is mounting that the spit and swab tests may be more convenient and just as accurate.
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Republicans have all but abandoned the Affordable Care Act as a campaign cudgel, judging from their national convention, at least. Meanwhile, career scientists at the federal government’s preeminent health agencies — the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health — are all coming under increasing political pressure as the pandemic drags on. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, Rovner interviews KHN’s Elizabeth Lawrence about the latest KHN-NPR “Bill of the Month” installment.
About 60% of poll respondents are worried that federal regulators will rush to allow a vaccine because of political pressure. Opposition to getting a vaccine that might be authorized before the November election is strongest among Republicans.
The FDA, under pressure from the Trump administration, has authorized broader use of convalescent plasma for emergency treatment in COVID patients. But several major hospitals are resisting, saying they’ll opt instead to use the scarce resource to complete a clinical trial.
President Donald Trump touted the Food and Drug Administration’s approval of this unproven COVID-19 treatment for emergency use. That set off reactions ranging from excitement and optimism to scientific concerns and criticism that the decision was politically motivated.
© 2026 KFF